SRR2932820
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.490
- OXIDATIVE_PHOSPHORYLATION+0.360
- HYPOXIA+0.340
- CHOLESTEROL_HOMEOSTASIS+0.330
- APOPTOSIS+0.320
- MTORC1_SIGNALING+0.310
- ANDROGEN_RESPONSE+0.300
- HEDGEHOG_SIGNALING+0.290
- P53_PATHWAY+0.280
- TGF_BETA_SIGNALING+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.260
- NOTCH_SIGNALING-0.240
- MYC_TARGETS_V2-0.230
- ALLOGRAFT_REJECTION-0.210
- E2F_TARGETS-0.210
- INTERFERON_GAMMA_RESPONSE-0.190
- G2M_CHECKPOINT-0.080
- DNA_REPAIR-0.060
- KRAS_SIGNALING_UP-0.050
- WNT_BETA_CATENIN_SIGNALING-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8F5717EC-3344-48CA-9B0C-FCDED8C0F955 | — | — | 0.795 |
| 2 | MNG329 | — | — | 0.782 |
| 3 | MNG967 | — | — | 0.769 |
| 4 | da1c4d8d-b07a-4aa1-8360-1c140ca16327 | — | — | 0.767 |
| 5 | SRR1313119 | — | A | 0.761 |
| 6 | MNG1171 | — | — | 0.748 |
| 7 | 618FAB92-C578-4144-9BD0-AEE1AFBFA08E | — | — | 0.746 |
| 8 | SRR1313167 | — | C | 0.745 |
| 9 | BSR_06_0059_A2_S99 | — | F | 0.739 |
| 10 | 106E2A94-0366-4D5E-894F-41117C78E18C | — | — | 0.737 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |